SCHEMBL4157658

SCHEMBL4157658

CCOC(=O)C(CCOC)(C(=O)OCC)[C@@H]1c2ccccc2C[C@H]1NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
EPHX2 P34913 1/20 0.38
MAOB P27338 2/20 0.36
MAOA P21397 1/20 0.36
KDM1A O60341 2/20 0.35
DRD2 P14416 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
PTPRB P23467 2/20 0.34
PDE4B Q07343 1/20 0.34
KCNH2 Q12809 2/20 0.33
NTRK1 P04629 1/20 0.33
MAPK14 Q16539 1/20 0.33
GHSR Q92847 1/20 0.33
NAMPT P43490 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
NR1I2 O75469 1/20 0.33
PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324391 1.00 ATM (0.43) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL3328789 0.96 ATM (0.41) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL3328783 0.93 EPHX2 (0.41) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL3323909 0.89 EPHX2 (0.41) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL13299071 0.88 ATM (0.40) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL13299075 0.87 EPHX2 (0.39) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL4157662 0.83 NFKB1 (0.35) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL3323474 0.83 ATM (0.40) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL3327727 0.83 EPHX2 (0.39) ATMEPHX2MAOBMAOAKDM1A
SCHEMBL4143264 0.82 ATM (0.45) ATMEPHX2MAOBMAOAKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 US disclosed
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 US disclosed
EP-1848693-A1 INDAN-AMIDE DERIVATIVES WITH GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-10-31 EP disclosed
WO-2006082400-A1 INDAN-AMIDE DERIVATIVES WITH GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity PYGL, PYGM, GYS1 ATM 2233/4885EPHX2 3678/4885MAOB 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.